Recorded Sessions from the APSARD 2017 Annual Meeting
Please note members must be logged into to view and request CME credit. Please log in and click view presentations at the bottom of the page.
Acknowledgment of Commercial Support
No commercial support was received for this enduring material.
Satisfactory Completion: Participants must pass post-test and complete an online evaluation form to receive a continuing education certificate. Participants not fulfilling these requirements will not receive a certificate. Certificates are available immediately after completing the online form.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and American Professional Society of ADHD & Related Disorders. Amedco is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Amedco designates this enduring material for a maximum of 11.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Session 1 – “Are Subsyndromal Manifestations of Disorders Meaningful?” – 2.0 hours
Learning objectives:
- Summarize clinical and scientific importance of subthreshold diagnoses in pediatric psychiatry.
- Talk about clinical examples of conditions in which a subthreshold diagnosis was specifically assessed.
- Explain the scientific and therapeutic implications of considering subthreshold diagnoses in practice.
Session 2 – “Current Issues and Mandates in Preschool ADHD” – 2.5 hours
Learning objectives:
- Identify the primary treatment modalities with empirical support for managing ADHD in preschool-aged children.
- Explain the developmental trajectories of young children at risk for ADHD and how they are related to clinical outcomes.
- Identify the regulatory environment for approving treatments for preschool children with ADHD.
Session 3 – “ADHD in College Students” – 1.75 hours
Learning objectives:
- Explain how ADHD and its associated features and functional impairments unfold across the first four years of college and are moderated/mediated by demographics and other variables of clinical interest.
- Identify opportunities for college student stimulant diversion prevention within the primary care setting.
- Summarize current controversies in the provision of testing accommodations to college students with ADHD, making reference to relevant research where appropriate.
- Explain how to increase knowledge of associations between ADHD stigma and ADHD malingering in college students.
Session 4 – “A Mindfulness Intervention for ADHD in Adulthood” – 2.0 hours
Learning objectives:
- Define mindfulness-based interventions (MBIs).
- Describe the rationale for applying MBIs to adults with ADHD.
- State how to establish the evidence-base of MBIs for ADHD in adulthood.
- List details of a MBI adapted for adults with ADHD.
Session 5 – “A Data-Driven Approach to Understanding ADHD in Females Across the Lifespan” – 1.75 hours
Learning objectives:
- Identify the elevated risk for multiple serious comorbid conditions as girls with ADHD enter young adulthood.
- Explain the differing patterns of neurological development in male and female brains and how these differences affect the presentation of ADHD at different developmental stages.
- Identify how changing hormonal levels in the brains of females can impact executive functioning.
- Explain how social problems in females with ADHD change from childhood, through adolescence and into adulthood.
Session 6 – “Stimulant vs. Nonstimulant Treatment of ADHD and Related Disorders” – 1.5 hours
Learning objectives:
- Name similarities and differences in mechanism of action of stimulant and non-stimulant medications for ADHD.
- State the differences in comparative effectiveness between stimulant and nonstimulant medications for ADHD.
- Explain the relative impact of prior treatment on efficacy of the different medications.
- Summarize the potential impact of comorbid aggression, tic disorders and substance abuse on treatment selection in individuals with ADHD.
Date of Release – March 20, 2017
Date of Expiration – December 31, 2018
Contact Information
If you have questions regarding this enduring material activity, please contact us at info@apsard.org
Disclosure Information
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content of CME disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CME are listed below.
| Last Name | First Name | Organization | Relationship |
| Anastopoulos | Arthur | N/A | N/A |
| Antshel | Keven | N/A | N/A |
| Biederman | Joseph | Avekshan LLC
Alcobra APSARD Lundbeck Merck Neurocentria Inc PamLab Pfizer Shire Pharmaceuticals Inc Sprites Sunovion |
Consultant
Honorarium Honorarium Research Support Research Support Research Support Research Support Research Support Research Support Research Support Research Support |
| Coffey | Barbara | Auspex/Teva
Catalyst Pharmaceuticals Genco Sciences Neurocrine Biosciences Shire |
Research Support; Advisory Board
Research Support Advisory Board Research Support Research Support |
| Collins | Erin | N/A | N/A |
| Epperson | Neill | Shire | Research Grant |
| Faraone | Stephen | N/A | N/A |
| Gur | Raquel | N/A | N/A |
| Halperin | Jeff | N/A | N/A |
| Kollins | Scott | Akili Interactive
Alcobra Atentiv Ironshore Medgenics Arbor Neos Neurovances Rhodes Shire SK Life Sciences Sunovion Tris |
Consultant & Research Support
Consultant Consultant Consultant Research Support Research Support Research Support Consultant & Research Support Consultant & Research Support Consultant & Research Support Consultant Research Support Consultant & Research Support |
| Lewandowski | Larry | N/A | N/A |
| Mahone | Mark | N/A | N/A |
| Mitchell | John | N/A | N/A |
| Nadeau | Katherine | N/A | N/A |
| Newcorn | Jeffrey | Alcobora
Cerecor Enzymotec Ironshore Neos NLS Rhodes Shire Sunovion Arbor Lundbeck |
Advisor/Consultant
Advisor Consultant/Research Funds Advisor/Consultant Advisor/Consultant Consultant Advisor Consultant/Honorarium Data Safety Board Advisor Research Funds |
| Steven | Pliszka | Ironshore Pharmaceuticals | Research Support and Consulting/Advisory Board |